NCT03953898: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
- State
- Under way
- Phase
- Phase 2
- People
- 14 taking part
- Started
- 4 Aug 2020
- Primary completion
- 16 Jan 2024
- Arms
- Treatment (olaparib)
- Results
- Posted on the registry
- 17 May 2019: Trial registered
- 4 Aug 2020: Trial started
- 30 Mar 2025: Trial results posted